Drugs / EscharEx
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05157763 | Jun 2021 → May 2022 overdue | nodular basal cell carcinoma, superficial multifocal basal cell carcinoma | MediWound Ltd | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04817228 | Apr 2021 → May 2022 | ulcer of lower limbs | MediWound Ltd | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03588130 Comparator | Dec 2019 → Dec 2021 | ulcer of lower limbs | MediWound Ltd | Completed | No outcome recorded |
| Phase 2 | NCT02020746 Comparator | Jul 2014 → Dec 2017 | ulcer of lower limbs | MediWound Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EscharEx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02020746 ↗ |
| Known as | EX-02 | “Previous studies have shown positive initial results with EscharEx® (EX-02 formulation), a Bromelain-based enzymatic debridement agent in development for chronic wounds.” PMID 39763591 ↗ Jul 20241“The powder of EX-02 (8.1 g in each unit) should be reconstituted with 20 g sterile water for injection (WFI) to obtain 5% EX-02.” NCT04817228 ↗ |
| Modality | Protein / enzyme biologic | “a Bromelain-based enzymatic debridement agent” PMID 39763591 ↗ Jul 2024 |
| Route | Topical | “topically applied” NCT04817228 ↗ |